Corvus Pharmaceuticals, Inc. (CRVS) Financial Statements (2023 and earlier)

Company Profile

Business Address 863 MITTEN ROAD
BURLINGAME, CA 94010
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:42,30049,60056,70062,90069,50076,30066,500
Cash and cash equivalents13,15924,58828,47731,46063,45872,29558,915
Other undisclosed cash, cash equivalents, and short-term investments29,14125,01228,22331,4406,0424,0057,585
Receivables588503373373507276 
Prepaid expense25241262162280486711
Other current assets1023973951301289880
Other undisclosed current assets4223607969028971,5971,829
Total current assets:43,66451,27258,88564,36771,31278,75769,120
Noncurrent Assets
Operating lease, right-of-use asset2,2172,4672,7122,9523,1903,4201,264
Property, plant and equipment353447527364451539647
Long-term investments and receivables21,87725,91430,18133,37134,26636,32838,047
Long-term investments21,87725,91430,18133,37134,26636,32838,047
Other noncurrent assets129248236236236279316
Total noncurrent assets:24,57629,07633,65636,92338,14340,56640,274
TOTAL ASSETS:68,24080,34892,541101,290109,455119,323109,394
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3,3365,8004,3203,4423,7974,2675,112
Employee-related liabilities1,3431,2559471,8461,4091,629
Accounts payable1,9764,2272,6502,1891,5652,3342,865
Accrued liabilities1,360230415306386524618
Other undisclosed current liabilities7,4168,1785,8365,8235,8957,0387,248
Total current liabilities:10,75213,97810,1569,2659,69211,30512,360
Noncurrent Liabilities
Long-term debt and lease obligation: 1,6891,9992,3032,6012,870631
Liabilities, other than long-term debt1,373      
Operating lease, liability1,3731,6891,9992,3032,6012,870631
Other undisclosed noncurrent liabilities (1,689)(1,999)(2,303)(2,601)(2,870)(631)
Total noncurrent liabilities:1,3731,6891,9992,303 2,870631
Total liabilities:12,12515,66712,15511,56812,29314,17512,991
Equity
Equity, attributable to parent56,11564,68180,38689,72297,162105,14896,403
Common stock5555554
Additional paid in capital364,361363,741363,083362,408361,669360,913341,484
Accumulated other comprehensive income (loss)(563)(1,193)3391,9871,8691,3751,387
Accumulated deficit(307,688)(297,872)(283,041)(274,678)(266,381)(257,145)(246,472)
Total equity:56,11564,68180,38689,72297,162105,14896,403
TOTAL LIABILITIES AND EQUITY:68,24080,34892,541101,290109,455119,323109,394

Income Statement (P&L) ($ in thousands)

12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
Operating expenses(5,666)(12,473)(7,013)(7,413)(6,810)(9,047)(11,290)
Other undisclosed operating income 2,7301,5961,041 1,709463
Operating loss:(5,666)(12,473)(7,013)(7,413)(6,810)(9,047)(11,290)
Loss from continuing operations before equity method investments, income taxes:(5,666)(12,473)(7,013)(7,413)(6,810)(9,047)(11,290)
Other undisclosed loss from continuing operations before income taxes(8,742)   (4,611)  
Loss from continuing operations:(14,408)(12,473)(7,013)(7,413)(11,421)(9,047)(11,290)
Loss before gain (loss) on sale of properties:(12,473)(7,013)(7,413)(11,421)(9,047)(11,290)
Other undisclosed net income (loss)4,592  (884)2,185  
Net loss:(9,816)(12,473)(7,013)(8,297)(9,236)(9,047)(11,290)
Other undisclosed net loss attributable to parent (2,358)(1,350)  (1,626)(462)
Net loss available to common stockholders, diluted:(9,816)(14,831)(8,363)(8,297)(9,236)(10,673)(11,752)

Comprehensive Income ($ in thousands)

12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
Net loss:(9,816)(12,473)(7,013)(8,297)(9,236)(9,047)(11,290)
Comprehensive loss:(9,816)(12,473)(7,013)(8,297)(9,236)(9,047)(11,290)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent630(3,890)(2,998)118494(1,638)919
Comprehensive loss, net of tax, attributable to parent:(9,186)(16,363)(10,011)(8,179)(8,742)(10,685)(10,371)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: